Related Experiment Videos
Common genetic variants in dyslipidemia, inflammation, and angiogenesis pathways associated with diabetic nephropathy
Amira Moussa1, Jabeur Methnani2, Refka Hassine2,3
1Biochemistry Department, Sahloul University Hospital, Sousse, LR12SP11, Tunisia. moussaamira@ymail.com.
Introduction:
Dyslipidemia, inflammation and angiogenesis pathways contribute to the genetic susceptibility to diabetic nephropathy (DN) in type 2 diabetes mellitus (T2DM). This study investigated the association of common genetic variants; Apolipoprotein C1 (APOC1) rs4420638, C-C chemokine receptor type 5 (CCR5) rs1799987, C-X-C motif chemokine ligand 8 (CXCL8) rs4073, Matrix metallopeptidase 9 (MMP9) rs17576, Erythropoietin (EPO) rs1617640 and Vascular Endothelial Growth Factor A (VEGFA) (rs833061 and rs3025039) with DN susceptibility in Tunisian T2DM patients.
Materials And Methods:
A total of 236 patients with T2DM were enrolled, including 47 with DN and 189 without diabetic nephropathy (WDN). Genotyping was performed using PCR-RFLP. Allelic combinations and statistical analyses were conducted using SNP Analyzer2.0 and SPSS20, respectively.
Results:
All genotype frequencies were in Hardy-Weinberg equilibrium. After adjustment for potential confounding factors, the variant alleles of APOC1 rs4420638 (OR = 2.58, 95% CI: 1.01-6.63, p = 0.048) and CXCL8 rs4073 (OR = 2.66, 95% CI: 1.06-6.65, p = 0.037) were independently associated with an increased risk of DN. Combined allelic profiles were associated with higher estimated DN risk, with the APOC1-CXCL8 (GT) combination showing an OR of 3.43 (95% CI: 1.08-10.80, p = 0.036).
Conclusion:
APOC1 rs4420638 and CXCL8 rs4073 seem to be associated with DN risk in Tunisian T2DM patients both individually and within multilocus genetic profiles.
Related Concept Videos
Type II Diabetes I: Introduction
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenomics: Identification of New Drug Targets
Coronary Artery Disease I: Introduction
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Principles of Pharmacogenetics: Types of Genetic Variants